| abstract |
The present invention relates to azazepine fused ring compounds and their medical uses. Specifically, the present invention relates to an azazepine fused ring compound represented by the general formula (I), its preparation method, a pharmaceutical composition comprising the same, and its use as a receptor-interacting protein kinase 1 (RIP1) inhibitor in the treatment of diseases associated with RIP1 activity. The definition of each substituent in the general formula (I) is the same as the definition in the specification. |